---
figid: PMC4580658__13555_2015_80_Fig1_HTML
figtitle: Schematic diagram showing select signaling pathways in melanoma
organisms:
- NA
pmcid: PMC4580658
filename: 13555_2015_80_Fig1_HTML.jpg
figlink: /pmc/articles/PMC4580658/figure/Fig1/
number: F1
caption: Schematic diagram showing select signaling pathways in melanoma. With activating
  BRAF mutations present in 50% of melanoma tumors and NRAS mutations present in approximately
  20%, the MAP kinase pathway (RAS-RAF-MEK-ERK) plays an important role in the majority
  of melanomas. However, other pathways also can contribute to pathogenesis and resistance
  to BRAF and MEK inhibition, such as activation of the PI3K pathway and signaling
  through COT and CDK4
papertitle: The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma.
reftext: Lijo John, et al. Dermatol Ther (Heidelb). 2015 Sep;5(3):151-169.
year: '2015'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.962987
figid_alias: PMC4580658__F1
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC4580658__F1
ndex: 73b53986-ded8-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4580658__13555_2015_80_Fig1_HTML.html
  '@type': Dataset
  description: Schematic diagram showing select signaling pathways in melanoma. With
    activating BRAF mutations present in 50% of melanoma tumors and NRAS mutations
    present in approximately 20%, the MAP kinase pathway (RAS-RAF-MEK-ERK) plays an
    important role in the majority of melanomas. However, other pathways also can
    contribute to pathogenesis and resistance to BRAF and MEK inhibition, such as
    activation of the PI3K pathway and signaling through COT and CDK4
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - egr
  - btl
  - htl
  - Sos
  - drk
  - ras
  - Ras64B
  - Ras85D
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Raf
  - Pten
  - Akt
  - Crtc
  - mir-ban
  - Dsor1
  - rl
  - CycD
  - Ets21C
  - Ets65A
  - pnt
  - Ets96B
  - Ets97D
  - Ets98B
  - Myc
  - Cdk4
  - Zdhhc8
  - Arpc5
  - Su(osk)P16
  - EGR1
  - EGR2
  - EGR3
  - EGR4
  - FGFR1
  - FGFR2
  - FGFR3
  - FGFR4
  - FGFRL1
  - PDGFRB
  - PDGFRA
  - XYLT2
  - SOS1
  - SOS2
  - GRB2
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - ARAF
  - RAF1
  - PTEN
  - BRAF
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - RPTOR
  - MAP3K8
  - CROT
  - MAP2K1
  - MAP2K2
  - MAPK3
  - MAPK1
  - CCND1
  - CCND2
  - CCND3
  - ETS1
  - ETS2
  - ELK1
  - KCNH4
  - KCNH8
  - MYC
  - CDK4
  - CDKN2A
  - H3P10
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
